Vertex Pharmaceuticals (VRTX) is at a critical turning point with its lead kidney drug, povetacicept, a potential treatment for IgA Nephropathy, as investors prepare for an imminent Phase 3 data readout that could define the drug's commercial future, RBC Capital Markets said in a report Tuesday.

The investment bank said, the market is currently debating whether the upcoming results can meet the high "bar" for success in an increasingly crowded competitive landscape.

Analysts at RBC said the 36-week "interim" readout, which could come as early as this week and possibly alongside Vertex's quarterly earnings, is expected to show 45% to 55% proteinuria reductions that would "support statistical significance" with clean safety and reinforce enthusiasm for povetacicept's multi-billion-dollar potential across kidney and autoimmune indications, according to the report.

Despite competitive pressure, RBC said it remains positive on Vertex, citing strong Phase II-to-Phase III data translatability, manageable demographic variables, and the company's durable cystic fibrosis franchise, adding that the current share levels do not fully reflect the upside potential from its kidney pipeline.

RBC has an outperform rating on Vertex Pharmaceuticals, with a price target of $546.

Price: 469.09, Change: -1.78, Percent Change: -0.38